62774-90-7

Basic information

• Product Name: 2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid
• Synonyms: 2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid;2,6-dichloro-4-methylnicotinic acid;3-Pyridinecarboxylic acid, 2,6-dichloro-4-Methyl-;2,6-dichloro-4-methylpyridine-3-carboxylic acid;62774-90-7
• CAS NO: 62774-90-7
• Molecular Formula: C₇H₅Cl₂NO₂
• Molecular Weight: 206.0261
• Product Categories: pharmacetical;Heterocycle-Pyridine series
• Mol File: 62774-90-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 140-141 °C
• Boiling Point: 370.1°C at 760 mmHg
• Flash Point: 177.6°C
• Appearance: /
• Density: 1.522g/cm³
• Vapor Pressure: 3.93E-06mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.55±0.38(Predicted)
• CAS DataBase Reference: 2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid(62774-90-7)
• EPA Substance Registry System: 2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid(62774-90-7)

Safety Data

• Hazardous Substances Data: 62774-90-7(Hazardous Substances Data)

Usage

General Description

2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid, also known as ciprofloxacin, is a broad-spectrum fluoroquinolone antibiotic used to treat a variety of bacterial infections. The chemical structure of ciprofloxacin consists of a pyridine ring with a carboxylic acid group and two chlorine atoms at the 2 and 6 positions, along with a methyl group at the 4 position. This chemical compound works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential enzymes for DNA replication and repair in bacteria. Ciprofloxacin is effective against a wide range of gram-negative and gram-positive bacteria, making it a commonly prescribed antibiotic for urinary tract infections, respiratory tract infections, skin infections, and other bacterial illnesses. However,

InChI:InChI=1/C7H5Cl2NO2/c1-3-2-4(8)10-6(9)5(3)7(11)12/h2H,1H3,(H,11,12)

Upstream product

• 875-35-4 2,6-dichloro-4-methylnicotinonitrile 
• 5444-02-0 3-cyano-4-methyl-6-hydroxypyrid-2-one 
• 38841-54-2 2,6-dichloro-4-methyl-3-pyridinecarboxamide 
• 91591-70-7 2,6-dichloro-4-methyl-3-pyridinecarboxaldehyde 

Relevant articles and documents

Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase

Previous studies have identified a series of imidazo[1,2-a]pyridine (IZP) derivatives as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) and virus infection in cell culture. However, IZPs were also found to be relatively potent activators of the pregnane-X receptor (PXR), raising the specter of induction of CYP-mediated drug disposition pathways. In an attempt to modify PXR activity without affecting anti-HIV-1 activity, rational structure-based design and modeling approaches were used. An X-ray cocrystal structure of (S,S)-1 in the PXR ligand binding domain (LBD) allowed an examination of the potential of rational structural modifications designed to abrogate PXR. The introduction of bulky basic amines at the C-8 position provided macrocyclic IZP derivatives that displayed potent HIV-1 inhibitory activity in cell culture with no detectable PXR transactivation at the highest concentration tested.

1,6-naphthyridine derivatives and their use to treat diabetes and related disorders

The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.

Antibacterial compounds

Antibacterials having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.